Article Text

SAT0073 Good Therapeutic Response with Biologics but Patients' and Physicians' Opinion Are Different. Data from The Austrian Bioreg Registry
  1. M. Herold1,2,
  2. G. Eichbauer-Sturm3,
  3. R. Puchner4,
  4. B. Rintelen5,
  5. F.S. Singer2,
  6. B.F. Leeb5
  1. 1Internal Medicine VI, Medical University of Innsbruck, Innsbruck
  2. 2BioReg Austria, Vienna
  3. 3Rheumatologist in private practice, Linz
  4. 4Rheumatologist in private practice, Wels
  5. 5Lower Austrian State Hospital Stockerau, 2nd Department of Internal Medicine, Karl Landsteiner Department of Clinical Rheumatology, Stockerau, Austria


Background The discordance between patients and physicians in estimation of patients' global health is well known especially from RA patients. We tried to find out whether differences in global health estimation are the same in patients with different diseases using data of the Austrian biologic registry.

Objectives The aim of this evaluation was to elucidate the amount of differences between PGA (Patient Global disease Activity) and EGA (Evaluator's Global disease Activity) in patients with rheumatoid arthritis (RA), spondylarthritis (SpA) and psoriatic arthritis (PsA) at baseline and at control visits every six months after inclusion in BioReg.

Methods Data were extracted from the Austrian BioReg registry ( was initiated in 2009 to document patients treated with one of the nine biologics (abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab) approved in Austria. Patients with ongoing biologic therapy as well as biologic-naïve patients starting biologic therapy can be included (baseline, BL). Further documentation is recommended about every six months (V1, V2 up to V11). Meanwhile, 1663 patients (rheumatoid arthritis (RA) n=948, ankylosing spondylitis (SpA) n=400, psoriatic arthritis (PsA) n=267, other disease n=48) have been documented. Estimation of global health is done using a visual analogue scale (VAS with 100 mm, 0 = no disease) by patients (PGA) and by physicians (EGA) at every visit.

Results VAS (median values of BL; V1; V2; V3; V4; V5) of patients with RA showed differences between PGA (30; 20; 22; 20; 20; 20) and EGA (15; 7; 10; 10; 10) as well as in SpA (PGA 39; 30; 26; 30; 30; 20 and EGA 20; 10; 10; 10; 10; 10) and in PSA (PGA 30; 10; 12; 20; 20; 10 and EGA 20; 10; 5; 10; 10; 10). Median values of inflammation's laboratory markers (ESR in mm/1st hour and CRP in mg/l) were always within the normal range (ESR and CRP in RA 5; 12; 14; 12; 14; 14 and 2,0; 2,0; 2,2; 2,0; 2,0; 2,0; in SpA: 7; 7; 7; 8; 7; 7 and 1,5; 1, 5; 1,7; 1,4; 1,2; 1,1 and in PsA 8; 8,5; 9; 9; 10; 10 and2,0; 1,7; 1,4; 1,0; 1,0; 1,0).

Conclusions As described for RA we also saw in patients with RA but also in SpA and PsA, that physicians' estimation of global health is always better than patients' values at all visits. We suppose that physicians focus primarily on signs of active inflammation and less on general feeling. The normal values of ESR and CRP support this assumption.

  1. Isabel Castrejon et al. Discordance of Global Estimates by Patients and Their Physicians in Usual Care of Many Rheumatic Diseases: Association With 5 Scores on a Multidimensional Health Assessment Questionnaire (MDHAQ) That Are Not Found on the Health Assessment Questionnaire (HAQ). Arthritis Care Res 2014;66:934–42

  2. Furu M et al. Discordance and accordance between patient's and physician's assessments in rheumatoid arthritis. Scand J Rheumatol 2014;43:291–5

Acknowledgement BIOREG is supported by an unlimited industrial grant.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.